Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7347849 | 0.81 | LMNA (0.41) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| SCHEMBL19758123 | 0.79 | TRPA1 (0.44) | MTNR1AMTNR1BLMNAKDM4ESLC6A4 | |
| SCHEMBL14653108 | 0.79 | TRPA1 (0.44) | MTNR1AMTNR1BLMNAKDM4ESLC6A4 | |
| SCHEMBL17896199 | 0.79 | TRPA1 (0.44) | MTNR1AMTNR1BLMNAKDM4ESLC6A4 | |
| SCHEMBL5729049 | 0.78 | MTNR1A (0.50) | TAAR1MAOAPTGS1MTNR1AMTNR1B | |
| SCHEMBL3160069 | 0.78 | MTNR1A (0.50) | TAAR1MAOAPTGS1MTNR1AMTNR1B | |
| SCHEMBL19758141 | 0.78 | LMNA (0.57) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| Bromide SCHEMBL11719047 | 0.77 | MTNR1A (0.49) | TAAR1MAOAPTGS1MTNR1AMTNR1B | |
| SCHEMBL28546046 | 0.76 | SLC6A4 (0.39) | MAOAPTGS1MTNR1AMTNR1BLMNA | |
| SCHEMBL7971270 | 0.73 | TAAR1 (0.42) | TAAR1MAOAPTGS1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | TAAR1 1298/4885MAOA 12/4885PTGS1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.